0000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202022-08-042022-08-04

Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 4, 2022

Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston, Massachusetts 02210
(Address of principal executive offices) (Zip Code)

(617) 341-6100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition.
On August 4, 2022, we issued a press release in which we reported our consolidated financial results for the three and six months ended June 30, 2022. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

ExhibitDescription of Document
104Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 4, 2022
/s/ Joy Liu
Joy Liu
Senior Vice President, General Counsel

EX-99.1 2 ex-991_q22022.htm EX-99.1 Document

Vertex Reports Second Quarter 2022 Financial Results
— Product revenues of $2.20 billion, a 22% increase compared to Q2 2021 —
— Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion —
— Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta thalassemia and type 1 diabetes—

— Multiple clinical programs entering or progressing through late-stage clinical development—

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2022 and updated its full year 2022 financial guidance.

“With sustained and growing leadership in CF, programs in five disease areas now entering or progressing through late-stage clinical development and the next wave of innovation beginning to enter the clinic later this year, Vertex has reached a new inflection point,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “As we reach more CF patients, we are poised to deliver significant, durable financial returns for years to come. In parallel, we are advancing a broad and deep clinical pipeline of potentially transformative medicines across multiple serious diseases, spanning small molecules, cell and genetic therapies, and we expect this diversified portfolio of medicines will serve many more patients and drive substantial growth in the future.”

Second Quarter 2022 Financial Highlights
Three Months Ended June 30,%
(in millions, except per share amounts)
Product revenues, net$2,196 $1,793 22%
TRIKAFTA/KAFTRIO$1,893 $1,256 
ORKAMBI$122 $221 
KALYDECO$139 $183 
GAAP operating income (loss)$1,106 $(38)
Non-GAAP operating income *$1,187 $71 
GAAP net income$810 $67 
Non-GAAP net income *$930 $43 
GAAP net income per share - diluted$3.13 $0.26 
Non-GAAP net income per share - diluted *$3.60 $0.17 
*Starting in the first quarter of 2022, Vertex no longer excludes research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from its Non-GAAP financial measures. Non-GAAP financial measures for the second quarter of 2021 have been recast to reflect this change.

Product revenues increased 22% to $2.20 billion compared to the second quarter of 2021, primarily driven by the strong uptake of TRIKAFTA/KAFTRIO in multiple countries internationally and continued strong performance of TRIKAFTA in the U.S., including the June 2021 launch of TRIKAFTA in children 6-11 years old in the U.S. Net product revenues in the second quarter of 2022 increased 13% to $1.42 billion in the U.S. and increased 46% to $781 million outside the U.S., compared to the second quarter of 2021.
GAAP and Non-GAAP net income increased compared to the second quarter of 2021, primarily due to strong product revenue growth and a one-time $900 million payment in connection with the amendment of Vertex's collaboration with CRISPR Therapeutics in the second quarter of 2021. The payment to CRISPR is included in acquired in-process research and development expenses ("Acquired IPR&D") in the second quarter of 2021.
Cash, cash equivalents and marketable securities as of June 30, 2022 were $9.3 billion, an increase of approximately $1.7 billion compared to December 31, 2021. The increase was primarily driven by strong revenue growth and operating cash flow.

Second Quarter 2022 Expenses
Three Months Ended June 30,
(in millions)
Combined GAAP R&D, Acquired IPR&D and SG&A expenses$877 $1,602 
Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses *$750 $1,496 
GAAP R&D expenses$600 $449 
Non-GAAP R&D expenses *$515 $383 
Acquired IPR&D *$62 $958 
GAAP SG&A expenses$215 $195 
Non-GAAP SG&A expenses$173 $154 
GAAP income taxes (1)$214 $(111)
Non-GAAP income taxes *$259 $11 
GAAP effective tax rate (1)21%251%
Non-GAAP effective tax rate22%20%
*Starting in the first quarter of 2022, Vertex no longer excludes research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from its Non-GAAP financial measures. These charges are included as "Acquired in-process research and development expenses," and were previously included in "Research and development expenses," in Vertex's consolidated statements of operations. Non-GAAP financial measures for the second quarter of 2021 have been recast to reflect this change.

Combined GAAP and Non-GAAP R&D, Acquired IPR&D and SG&A expenses decreased compared to the second quarter of 2021, primarily due to the one-time $900 million payment to CRISPR in the second quarter of 2021, partially offset by increased investment in support of multiple programs that have advanced in mid- and late-stage clinical development and the costs to support launches of Vertex's therapies globally.
GAAP and Non-GAAP income taxes increased compared to the second quarter of 2021, primarily due to the income tax impact of the $900 million payment to CRISPR in the second quarter of 2021. GAAP income taxes also increased due to a discrete tax benefit recorded in the second quarter of 2021. Please refer to Note 1 for further details.

Full Year 2022 Financial Guidance
Vertex is raising its full year 2022 product revenue guidance to $8.6 to $8.8 billion. The increase primarily reflects the robust uptake of KAFTRIO/TRIKAFTA in countries outside the U.S. where Vertex has recently achieved reimbursement. Vertex is also increasing full year 2022 combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expense guidance. The increase results from the advancement of the company's clinical pipeline, including a number of programs that have recently entered or are initiating late-stage development, and from incremental expenses related to recent business development activity.

Updated guidance is summarized below:
Current FY 2022Previous FY 2022
Product revenues$8.6 to $8.8 billion$8.4 to $8.6 billion
Combined GAAP R&D, Acquired IPR&D and SG&A expenses (2)$3.48 to $3.63 billion$3.30 to $3.45 billion
Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses (2) *$3.0 to $3.1 billion$2.82 to $2.92 billion
Non-GAAP effective tax rateUnchanged21% to 22%
*Starting in the first quarter of 2022, Vertex no longer excludes research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from its Non-GAAP financial measures. These charges are included as "Acquired in-process research and development expenses," and were previously included in "Research and development expenses," in Vertex's consolidated statements of operations.

Key Business Highlights

Cystic Fibrosis (CF) Marketed Products
Vertex anticipates the number of CF patients treated with its medicines will continue to grow as a result of the uptake of TRIKAFTA in the U.S. and the launches of KAFTRIO outside the U.S., additional reimbursement agreements outside the U.S., and new approvals for the treatment of younger patients. Recent progress includes:
Vertex has completed the Phase 3 study of TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children 2 to 5 years old. Data from this study showed similarly compelling efficacy of TRIKAFTA/KAFTRIO in children 2 to 5 years old to other age groups and no new safety findings. The Company expects to present the results at a medical forum later in 2022. Vertex anticipates submitting global regulatory filings for TRIKAFTA/KAFTRIO in children 2 to 5 years old this year.

At the European Cystic Fibrosis Society's (ECFS) European Cystic Fibrosis Conference in June, Vertex presented data from the U.S. CF Foundation Patient Registry (CFFPR) of more than 16,000 people treated with TRIKAFTA for an average of nine months, showing that treatment with TRIKAFTA was associated with improved lung function and reduced risk of pulmonary exacerbations compared to pre-TRIKAFTA baseline, as well as lower risks of lung transplant and death, compared to the historical 2019 U.S. CFFPR population. Vertex also presented data for TRIKAFTA demonstrating no loss in mean lung function in people with F/F and F/MF mutations over a two-year period, in contrast to declines seen in the matched controls.
In April, Health Canada granted marketing authorization for TRIKAFTA in children 6 to 11 years of age. With this approval, approximately 500 children with CF became newly eligible for treatment with a CFTR modulator. Vertex recently signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) paving the way for reimbursement of TRIKAFTA for this age group.
Vertex has filed a Supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for the use of ORKAMBI in children 12 months to less than 24 months old. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of September 4, 2022.

TRIKAFTA/KAFTRIO is now approved and reimbursed or accessible in more than 25 countries.

R&D pipeline
Vertex is delivering on a diversified pipeline of potentially transformative small molecule, cell and genetic therapies aimed at serious diseases. Recent and anticipated progress for key pipeline programs is summarized below.

Cystic Fibrosis
Vertex continues to pursue next-in-class, small molecule CFTR modulator therapies as well as new treatment options for the approximately 5,000 patients who cannot benefit from CFTR modulators.
Vertex is conducting two Phase 3 global, randomized, double-blind, active-controlled clinical trials (SKYLINE 102 and SKYLINE 103) evaluating Vertex’s new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 in patients with CF 12 years of age and older. The SKYLINE 102 and SKYLINE 103 trials will compare the efficacy and safety of VX-121/

tezacaftor/VX-561 to TRIKAFTA. More than 250 sites across both studies are active and enrolling patients. Enrollment in both trials is expected to be completed in late 2022 or early 2023.
In parallel to SKYLINE 102 and 103, Vertex has also initiated a study of VX-121/tezacaftor/VX-561 in children with CF 6 to 11 years of age.
In collaboration with Moderna, Vertex is developing CFTR mRNA therapeutics designed to treat the underlying cause of CF by programming cells in the lungs to produce functional CFTR protein for the treatment of the approximately 5,000 people with CF who do not produce any CFTR protein. IND-enabling studies have been completed, and Vertex is on track to submit an IND for this program in 2H 2022.

Beta Thalassemia and Sickle Cell Disease
The exa-cel (CTX001) program employs a non-viral ex vivo CRISPR gene-editing therapy, which is being developed as a potential functional cure for transfusion-dependent thalassemia (TDT) and severe sickle cell disease (SCD). Vertex is developing exa-cel in collaboration with CRISPR Therapeutics.
In June, at the European Hematology Association (EHA) Congress, Vertex and CRISPR presented data from 75 patients (44 with TDT, 31 with SCD) from the CLIMB-111, CLIMB-121 and CLIMB-131 studies with follow-up ranging from 1.2 to 37.2 months after exa-cel infusion. All 31 patients with severe SCD, characterized by recurrent vaso-occlusive crises (VOCs), were free of VOCs after exa-cel infusion through the duration of follow-up, with follow-up ranging from 2.0 to 32.3 months. Of the 44 patients with TDT, 42 were transfusion-free with follow-up ranging from 1.2 to 37.2 months. Two patients who were not yet transfusion-free had 75% and 89% reductions in transfusion volume, respectively. The safety profile was generally consistent with myeloablative conditioning with busulfan and autologous stem cell transplant.
Two additional Phase 3 studies of exa-cel have been initiated in pediatric patients, one in TDT and a second in SCD.
Vertex has completed discussions with the EMA and the Medicines and Healthcare products Regulatory Agency (MHRA) on the submission package for exa-cel and is on track to submit for regulatory approvals of exa-cel for SCD and TDT in Europe and the UK by the end of 2022. Discussions with the U.S. FDA are ongoing.

APOL1-Mediated Kidney Disease (AMKD)
Vertex has discovered multiple oral, small molecule inhibitors of APOL1, pioneering a new class of medicines that target an underlying genetic driver of kidney disease.

In March, Vertex initiated pivotal development of inaxaplin (VX-147) in a single Phase 2/3 study in patients with two APOL1 mutations and proteinuric kidney disease.
This Phase 2/3 adaptive study will first evaluate two doses of inaxaplin to select a dose for Phase 3 and subsequently evaluate the efficacy and safety of the single, selected dose in the Phase 3 portion of the study. The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the selected dose of inaxaplin compared to placebo at two years. The study is designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in proteinuria in the inaxaplin arm versus placebo. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD. Enrollment is ongoing, with more than 30 sites active in the U.S.
The U.S. FDA recently granted inaxaplin Breakthrough Therapy designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the EMA has also granted inaxaplin Priority Medicines (PRIME) designation for AMKD.

Pain (NaV1.8)
Vertex has discovered multiple selective small molecule inhibitors of NaV1.8 with the objective of creating a new class of pain medicines that have the potential to provide effective pain relief, without the limitations of opioids and other standard-of-care pain medicines.
In March, Vertex reported positive data from two Phase 2 dose-ranging acute pain studies with VX-548, one following bunionectomy surgery and the other following abdominoplasty surgery. Both studies met their primary endpoint and established proof of concept for VX-548.
Vertex has completed its end-of-phase 2 meeting with the FDA and has reached agreement on the design of the Phase 3 program in acute pain. The Phase 3 program will include two randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VX-548 for moderate to severe acute pain following bunionectomy or abdominoplasty surgery. Each study will also include a hydrocodone bitartrate/acetaminophen (HB/APAP) treatment arm. A third single-arm study will evaluate treatment with VX-548 for up to 14 days in multiple other types of moderate to severe acute pain. Vertex expects to initiate this program in the fourth quarter of 2022.
Vertex also intends to initiate a Phase 2 dose-ranging study of VX-548 in neuropathic pain by the end of 2022.
The U.S. FDA has granted VX-548 Breakthrough Therapy designation for moderate to severe acute pain.


Type 1 Diabetes (T1D)
Vertex is evaluating cell therapies using stem cell-derived islets to replace the endogenous insulin-producing islet cells that are destroyed in people with T1D, with the goal of developing a potential functional cure for this disease.
VX-880 is a stem cell-derived, fully differentiated islet replacement therapy, used in combination with standard immunosuppression to protect the implanted cells. VX-880 is being evaluated in a Phase 1/2 clinical trial for the treatment of T1D.
In June, at the American Diabetes Association (ADA) Scientific Sessions Conference, Vertex provided additional data on the two patients dosed at half the target dose in Part A of its VX-880 Phase 1/2 study. Vertex had previously reported that both patients had achieved glucose-responsive insulin production, improvements in glycemic control and reductions in exogenous insulin requirements. Additional data presented at ADA also showed significant increases in the blood glucose time-in-range compared to baseline, following treatment with VX-880. Patient 1 showed a blood glucose time-in-range increase from 40.1% at baseline to 99.9% at Day 270 and was insulin independent. Patient 2 showed a time-in-range increase from 35.9% at baseline to 51.9% at Day 150 with a 30% reduction in exogenous insulin use.
The VX-880 Phase 1/2 clinical trial has resumed enrollment in the U.S. Part B of the study is open for enrollment at sites in the U.S. and Canada.
Vertex is advancing additional programs in T1D, in which these same stem cell-derived islets are encapsulated and implanted in an immunoprotective device or modified to produce hypoimmune stem cell islets, with the goal of eliminating the need for immunosuppression.
Vertex is on track to submit an IND for the cells plus device program in 2022.

Alpha-1 Antitrypsin (AAT) Deficiency
Vertex is working to address the underlying genetic cause of alpha-1 antitrypsin (AAT) deficiency by developing novel small molecule correctors of Z-AAT protein folding, with the goal of increasing the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AAT deficiency.
Vertex is on track to advance one or more novel small molecule Z-AAT correctors into the clinic in 2022.


Duchenne Muscular Dystrophy (DMD)
Vertex is investigating a novel approach to treating DMD by delivering CRISPR/Cas9 gene-editing technology to muscle cells, with the goal of restoring near-full length dystrophin protein expression by targeting specific mutations in the dystrophin gene that cause the disease.
IND-enabling studies for the first in vivo gene editing therapy for DMD are underway. Vertex anticipates submitting an IND in 2023.

Consistent with its overall strategy, Vertex takes a portfolio approach to all of its programs, with additional assets in CF, SCD, Beta Thalassemia, AMKD, T1D, Pain, and AATD in earlier stages of development.

Investments in External Innovation
Consistent with its strategy to develop transformative medicines for serious diseases, Vertex recently entered into the following transactions:
In July, Vertex entered into a definitive agreement to acquire ViaCyte, a privately held company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes, for $320 million in cash. The acquisition will provide Vertex with complementary assets, capabilities and technologies that could accelerate Vertex's existing T1D programs. Vertex anticipates the acquisition will close later this year.
Also in July, Vertex entered into a research collaboration with Verve Therapeutics, focused on discovering and developing an in vivo gene editing program for a liver disease.
In May, Vertex acquired Catalyst Biosciences' complement portfolio and related intellectual property for $60 million in cash, adding capabilities in the area of complement-mediated diseases.


Non-GAAP Financial Measures
In this press release, Vertex's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, non-GAAP financial results and guidance exclude from Vertex's pre-tax income (i) stock-based compensation expense, (ii) gains or losses related to the fair value of the company's strategic investments, (iii) increases or decreases in the fair value of contingent consideration, (iv) acquisition-related costs, (v) an intangible asset impairment charge and (vi) other adjustments. The company's non-GAAP financial results also exclude from its provision for income taxes the estimated tax impact related to its non-GAAP adjustments to pre-tax income described above and certain discrete items. These results should not be viewed as a substitute for the company’s GAAP results and are provided as a complement to results provided in accordance with GAAP. Management believes these non-GAAP financial measures help indicate underlying trends in the company's business, are important in comparing current results with prior period results and provide additional information regarding the company's financial position that the company believes is helpful to an understanding of its ongoing business. Management also uses these non-GAAP financial measures to establish budgets and operational goals that are communicated internally and externally, to manage the company's business and to evaluate its performance. The company’s calculation of non-GAAP financial measures likely differs from the calculations used by other companies. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the attached financial information.
The company provides guidance regarding combined R&D, Acquired IPR&D and SG&A expenses and effective tax rate on a non-GAAP basis. The guidance regarding combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses does not include estimates associated with any potential future business development transactions, including collaborations, asset acquisitions and/or licensing of third-party intellectual property rights. The company does not provide guidance regarding its GAAP effective tax rate because it is unable to forecast with reasonable certainty the impact of excess tax benefits related to stock-based compensation and the possibility of certain discrete items, which could be material.

Vertex Pharmaceuticals Incorporated
Consolidated Statements of Operations
(in millions, except per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
Product revenues, net$2,196.2 $1,793.4 $4,293.7 $3,516.7 
Other revenues— — — 1.0 
Total revenues2,196.2 1,793.4 4,293.7 3,517.7 
Costs and expenses:
Cost of sales261.8 228.0 507.6 420.3 
Research and development expenses600.1 448.7 1,201.2 903.0 
Acquired in-process research and development expenses (3)61.9 958.4 63.9 960.1 
Selling, general and administrative expenses215.3 194.6 430.5 386.7 
Change in fair value of contingent consideration(49.2)1.6 (56.7)(2.3)
Total costs and expenses1,089.9 1,831.3 2,146.5 2,667.8 
Income (loss) from operations1,106.3 (37.9)2,147.2 849.9 
Interest income10.8 1.1 12.4 2.6 
Interest expense(14.6)(15.5)(29.5)(31.2)
Other (expense) income, net(78.1)8.1 (150.9)(44.6)
Income (loss) before provision for (benefit from) income taxes1,024.4 (44.2)1,979.2 776.7 
Provision for (benefit from) income taxes213.9 (111.2)406.6 56.6 
Net income$810.5 $67.0 $1,572.6 $720.1 
Net income per common share:
Basic$3.17 $0.26 $6.15 $2.78 
Diluted$3.13 $0.26 $6.09 $2.75 
Shares used in per share calculations:
Basic255.9 259.0 255.5 259.2 
Diluted258.7 261.0 258.3 261.5 

Vertex Pharmaceuticals Incorporated
Reconciliation of GAAP to Non-GAAP Net Income and Operating Income
(in millions, except per share amounts)

Three Months Ended June 30,Six Months Ended June 30,
GAAP net income$810.5 $67.0 $1,572.6 $720.1 
Stock-based compensation expense113.9 104.6 244.2 219.8 
Decrease (increase) in fair value of strategic investments (4)84.2 (10.6)159.8 41.7 
(Decrease) increase in fair value of contingent consideration (5)(49.2)1.6 (56.7)(2.3)
Intangible asset impairment charge (5)13.0 — 13.0 — 
Acquisition-related costs (6)2.8 2.8 5.6 5.6 
Total non-GAAP adjustments to pre-tax income *164.7 98.4 365.9 264.8 
Tax adjustments (1) *(44.7)(122.1)(100.9)(160.3)
Non-GAAP net income *$930.5 $43.3 $1,837.6 $824.6 
Net income per diluted common share:
GAAP$3.13 $0.26 $6.09 $2.75 
Non-GAAP *$3.60 $0.17 $7.11 $3.15 
Shares used in diluted per share calculations:
GAAP and Non-GAAP258.7 261.0 258.3 261.5 
Three Months Ended June 30,Six Months Ended June 30,
GAAP operating income (loss)$1,106.3 $(37.9)$2,147.2 $849.9 
Stock-based compensation expense113.9 104.6 244.2 219.8 
(Decrease) increase in fair value of contingent consideration (5)(49.2)1.6 (56.7)(2.3)
Intangible asset impairment charge (5)13.0 — 13.0 — 
Acquisition-related costs (6)2.8 2.8 5.6 5.6 
Non-GAAP operating income *$1,186.8 $71.1 $2,353.3 $1,073.0 


Vertex Pharmaceuticals Incorporated
Reconciliation of GAAP to Non-GAAP Expenses
(in millions, except percentages)

Three Months Ended June 30,Six Months Ended June 30,
GAAP cost of sales
$261.8 $228.0 $507.6 $420.3 
Stock-based compensation expense(2.4)(1.6)(4.6)(3.0)
Non-GAAP cost of sales
$259.4 $226.4 $503.0 $417.3 
GAAP research and development expenses$600.1 $448.7 $1,201.2 $903.0 
Stock-based compensation expense(69.5)(62.6)(149.9)(135.4)
Intangible asset impairment charge (5)(13.0)— (13.0)— 
Acquisition-related costs (6)(2.8)(2.8)(5.6)(5.6)
Non-GAAP research and development expenses *$514.8 $383.3 $1,032.7 $762.0 
Acquired in-process research and development expenses *$61.9 $958.4 $63.9 $960.1 
GAAP selling, general and administrative expenses$215.3 $194.6 $430.5 $386.7 
Stock-based compensation expense(42.0)(40.4)(89.7)(81.4)
Non-GAAP selling, general and administrative expenses$173.3 $154.2 $340.8 $305.3 
Combined non-GAAP R&D, Acquired IPR&D and SG&A expenses *$750.0 $1,495.9 $1,437.4 $2,027.4 
GAAP other (expense) income, net$(78.1)$8.1 $(150.9)$(44.6)
Decrease (increase) in fair value of strategic investments (4)84.2 (10.6)159.8 41.7 
Non-GAAP other income (expense), net$6.1 $(2.5)$8.9 $(2.9)
GAAP provision for (benefit from) income taxes$213.9 $(111.2)$406.6 $56.6 
Tax adjustments (1) *44.7 122.1 100.9 160.3 
Non-GAAP provision for income taxes *$258.6 $10.9 $507.5 $216.9 
GAAP effective tax rate21 %251 %21 %%
Non-GAAP effective tax rate22 %20 %22 %21 %
*Starting in the first quarter of 2022, Vertex no longer excludes research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third-party intellectual property rights from its Non-GAAP financial measures. These charges are included as "Acquired in-process research and development expenses," and were previously included in "Research and development expenses," in Vertex's consolidated statements of operations. Non-GAAP financial measures for the three and six months ended June 30, 2021 have been recast to reflect this change.

Vertex Pharmaceuticals Incorporated
Condensed Consolidated Balance Sheets
(in millions)

June 30, 2022December 31, 2021
Cash, cash equivalents and marketable securities$9,253.4 $7,524.9 
Accounts receivable, net1,332.9 1,136.8 
Inventories367.7 353.1 
Property and equipment, net1,100.1 1,094.1 
Goodwill and intangible assets1,389.2 1,402.2 
Deferred tax assets1,143.8 934.5 
Other assets995.1 986.9 
      Total assets$15,582.2 $13,432.5 
Liabilities and Shareholders' Equity
Accounts payable and accrued expenses$2,317.5 $1,873.6 
Finance lease liabilities531.6 556.7 
Contingent consideration129.8 186.5 
Other liabilities669.8 715.7 
Shareholders' equity11,933.5 10,100.0 
      Total liabilities and shareholders' equity$15,582.2 $13,432.5 
Common shares outstanding256.0 254.5 


Notes and Explanations
1: In the three and six months ended June 30, 2022 and 2021, "Tax adjustments" included the estimated income taxes related to non-GAAP adjustments to the company's pre-tax income (loss) and excess tax benefits related to stock-based compensation. "Tax adjustments" in the three and six months ended June 30, 2021 also included a $100 million discrete tax benefit related to an increase in the U.K.'s corporate tax rate from 19% to 25%, which was enacted in June 2021 and will become effective in April 2023.
2: The difference between the company’s full year 2022 combined GAAP R&D, Acquired IPR&D and SG&A expenses and combined non-GAAP R&D, Acquired IPR&D and SG&A expenses guidance relates primarily to $445 million to $500 million of stock-based compensation expense. The guidance regarding combined GAAP and non-GAAP R&D, Acquired IPR&D and SG&A expenses does not include estimates associated with any potential future business development transactions, including collaborations, asset acquisitions and/or licensing of third-party intellectual property rights.
3: Vertex classifies upfront, contingent milestone, and other payments pursuant to its business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development expenses” in its consolidated statements of operations. These amounts were previously classified as "Research and development expenses." To conform prior periods to current presentation, the company reclassified $958 million and $960 million from “Research and development expenses” to “Acquired in-process research and development expenses” for the three and six months ended June 30, 2021, respectively. In the three and six months ended June 30, 2021, "Acquired in-process research and development expenses" primarily related to the $900 million upfront payment to CRISPR.
4: "Other (expense) income, net" includes net gains and losses related to changes in the fair value of the company's strategic investments.
5: In June 2022, the company revised the scope of certain acquired programs, resulting in a $13 million “Intangible asset impairment charge” and a decrease in the associated fair value of contingent consideration.
6: "Acquisition-related costs" in the three and six months ended June 30, 2022 and 2021 related to costs associated with the company's acquisition of Exonics.
Note: Amounts may not foot due to rounding.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 12 consecutive years on Science magazine's Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, Dr. Kewalramani's statements in this press release, the information provided regarding future financial performance and operations, the section captioned "Full Year 2022 Financial Guidance" and statements regarding (i) anticipated regulatory discussions and filings, data availability, and timing thereof, (ii) the expectations, development plans and anticipated timelines for the company's products and product candidates and pipeline programs, including study designs, patient enrollment, data availability and timing thereof, (iii) expectations for continued growth in the number of CF patients treated with our medicines, including the number of children newly eligible for TRIKAFTA, uptake of and expanded access to the company’s medicines, additional reimbursement agreements, new approvals, including market authorizations and label extensions outside of the U.S., and expansion of treatment options for the patients who cannot benefit from CFTR modulators alone, (iv) expectations regarding our collaboration with Moderna to develop CF mRNA therapeutics, including our plans to submit an IND for this program in 2022, (v) expectations regarding two additional Phase 3 studies of exa-cel in pediatric patients and anticipated regulatory filings for exa-cel, (vi) our plans regarding our Phase 2/3 study of inaxaplin in AMKD, and our beliefs regarding anticipated results of the study and the possibility for accelerated approval in the U.S. and Europe, (vii) expectations regarding the potential benefits of our pain program and products, and plans for the advancement of VX-548 into a Phase 3 program in acute pain in the second half of 2022 and to initiate a Phase 2 study in neuropathic pain by the end of 2022, and the possibility for accelerated approval in the U.S., (viii) the potential benefits and safety of VX-880, and our plans to continue to progress the Phase 1/2 program for VX-880, (ix) our plans and expectations regarding our additional programs in T1D, including the completion of IND-enabling studies for the encapsulated islet cell program and anticipated regulatory filings in 2022, (x) plans to advance one or more novel small molecule Z-AAT correctors into the clinic in 2022, (xi) our plans regarding our DMD program, and (xii) our investments and expectations in external innovation, including collaborations and acquisitions. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the company's expectations regarding its

2022 product revenues, expenses and effective tax rates may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), that the company may not be able to submit the anticipated regulatory filings on the expected timeline, or at all, that external factors may have different or more significant impacts on the company's business or operations than the company currently expects, that data from preclinical testing or clinical trials, especially if based on a limited number of patients, may not be indicative of final results or available on anticipated timelines, that the company may not realize the anticipated benefits from our collaborations with third parties, that data from the company's development programs may not support registration or further development of its potential medicines in a timely manner, or at all, due to safety, efficacy or other reasons, and other risks listed under the heading “Risk Factors” in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC’s website at www.sec.gov. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

Conference Call and Webcast
The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1 (412) 902-6510 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2022 Earnings Call”.

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

Vertex Contacts:
Manisha Pai, 617-961-1899
Miroslava Minkova, 617-341-6135


EX-101.SCH 3 vrtx-20220804.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vrtx-20220804_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 vrtx-20220804_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information Document
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 04, 2022
Entity Central Index Key 0000875320
Amendment Flag false
Entity Incorporation, State or Country Code MA
Entity File Number 000-19319
Entity Tax Identification Number 04-3039129
Entity Address, Address Line One 50 Northern Avenue
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code 617
Local Phone Number 341-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share
Trading Symbol VRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 vrtx-20220804_htm.xml IDEA: XBRL DOCUMENT 0000875320 2022-08-04 2022-08-04 0000875320 VERTEX PHARMACEUTICALS INC / MA false 8-K 2022-08-04 MA 000-19319 04-3039129 50 Northern Avenue Boston MA 02210 617 341-6100 false false false false Common Stock, $0.01 Par Value Per Share VRTX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.vrtx.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports vrtx-20220804.htm ex-991_q22022.htm vrtx-20220804.xsd vrtx-20220804_lab.xml vrtx-20220804_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vrtx-20220804.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "vrtx-20220804.htm" ] }, "labelLink": { "local": [ "vrtx-20220804_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20220804_pre.xml" ] }, "schema": { "local": [ "vrtx-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220804.htm", "contextRef": "i82f203484293481aafca55b467828451_D20220804-20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.vrtx.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220804.htm", "contextRef": "i82f203484293481aafca55b467828451_D20220804-20220804", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000875320-22-000026-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-22-000026-xbrl.zip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end